Biotechs emerging from stealth take aim at pharma’s prime targets

The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

By Kelly Bilodeau • March 24, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

By Michael Gibney • March 20, 2025

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

By Alexandra Pecci • March 19, 2025

How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

By Michael Gibney • March 18, 2025

Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

By Kelly Bilodeau • March 17, 2025

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

By Amy Baxter • March 17, 2025

Takeda’s $770M deal deepens Big Pharma’s omics push

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

By Alexandra Pecci • March 13, 2025

The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

By Amy Baxter • March 11, 2025

What’s driving pharma’s layoffs in 2025

Familiar foes in the industry have claimed a slew of jobs in recent months.

By Meagan Parrish • March 10, 2025

The top 3 impacts of Trump’s health data purge

Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

By Michael Brady • March 6, 2025

With patent losses on the horizon, Amgen refocuses its business strategy

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

By Alexandra Pecci • March 5, 2025

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

By Jonathan Gardner • March 5, 2025

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

By Michael Gibney • March 4, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

By Michael Gibney • Feb. 27, 2025

Cancer vaccines have stumbled, but the approach is gaining new steam

The number of candidates in development has nearly doubled over the past 15 years.

By Kelly Bilodeau • Feb. 26, 2025

Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

By Alexandra Pecci • Feb. 25, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

By Alexandra Pecci • Feb. 19, 2025

CRISPR’s cardio catch-all drives a biotech’s broad potential

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

By Kelly Bilodeau • Feb. 18, 2025

In the crowded cardio space, it’s David vs. Goliath for small biotechs

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

By Alexandra Pecci • Feb. 11, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

Are orexins the next golden child of neuroscience?

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

By Meagan Parrish • Feb. 10, 2025